Breast Cancer
Conditions
Keywords
Doxorubcin, Breast cancer, Cardiotoxicity, Gene polymorphism
Brief summary
Recent advances in technologies, such as microarray and high-throughput sequencing, represented a deeper understanding of molecular biology, especially noncoding RNA (ncRNA). It was found that there are only \<2 % of the total genome sequence as protein-coding genes while at least 98 % of the genome are transcribed into ncRNA. In the past, non-protein-coding RNAs were known as transcription noise, but now it is obvious that ncRNAs play a crucial regulatory role in cell differentiation and organism growth and metabolism.
Interventions
None listed
Sponsors
Ain Shams University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Metastatic and localized breast cancer patients treated with Doxorubicin among chemotherapeutic protocol. * Measurable disease. * Age of 18 years to 80 years. * The women of childbearing age must use an effective contraception for the duration of the study.
Exclusion criteria
* Breast cancer patients who had undergone radiotherapy or chemotherapy. * Pregnant and lactating females. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to chemotherapeutic agents used. * Any other medical or psychiatric condition or severe or chronic laboratory abnormality making the inclusion of the patient in the study inappropriate in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cardiotoxicity | 6 months | Occurrence of dilated cardiomyopathy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Nephrotoxicity | 6 months | Occurrence of nephrotoxicity |
Countries
Egypt
Contacts
Primary ContactNeven Sarhan, PhD
Backup ContactMona Schaalan, PhD
Outcome results
None listed